Wegovy® pill approved in the US as first oral GLP-1 for weight management
Wegovy® pill showed a mean weight loss of 16.6% in the OASIS 4 trial Wegovy® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse cardiovascular events* Novo Nordisk expects to launch Wegovy® pill in the US in early January 2026 Dubai, 24 December 2025- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events*. The Wegovy®
Wegovy® pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Wegovy® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse cardiovascular events*
Novo Nordisk expects to launch Wegovy® pill in the US in early January 2026
Dubai, 24 December 2025- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events*.
The Wegovy®
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
